Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Borys Hrinczenko"'
Autor:
Orimisan Samuel Adekolujo, Ahsan Wahab, Maxwell Oluwole Akanbi, Tolutope Oyasiji, Borys Hrinczenko, Olatunji Boladale Alese
Publikováno v:
Cancer Biology & Therapy, Vol 24, Iss 1 (2023)
Despite recent advances in cancer therapeutics, pancreatic ductal adenocarcinoma (PDAC) remains a lethal disease with a 5-year overall survival of only 10%. Since either at or within a few months of diagnosis, most patients with PDAC will present wit
Externí odkaz:
https://doaj.org/article/7880abf3272e4970ad447f42a0a0fe35
Autor:
Yousef Zakharia MD, Joshua Mansour MD, Srinivasa Vasireddi MD, Kais Zakharia MD, Eduard Fatakhov MD, Christopher Koch, Borys Hrinczenko MD
Publikováno v:
Journal of Investigative Medicine High Impact Case Reports, Vol 2 (2014)
In the present case, a 49-year-old white female presented to the clinic with a 2-month history of nausea, vomiting, and right upper quadrant pain. On examination a 3-cm mass on the right anterior scalene muscle was noted. A computed tomography scan w
Externí odkaz:
https://doaj.org/article/8ee9e6daadfa4cbc95652e099e3b89bb
Autor:
Anas Al-Janadi, Borys Hrinczenko, Vijay Chaudhary, Shalini Chitneni, Sarah Ali, Jennifer Saultz, Nikolay V. Dimitrov
Publikováno v:
Oncology Reviews, Vol 4, Iss 3 (2011)
Musculoskeletal symptoms have been reported in patients treated with third generation aromatase inhibitors (AIs) and with blockers of hypothalamic–pituitary gonadal axis. AIs act by suppressing postmenopausal estrogen biosynthesis through inhibitio
Externí odkaz:
https://doaj.org/article/d9477a2e65ca4401984cd5e264d3f3af
Autor:
Borys Hrinczenko, Nicholas Iannotti, Sanjay Goel, David Spigel, Howard Safran, Matthew H Taylor, Jaafar Bennouna, Deborah J Wong, Karen Kelly, Claire Verschraegen, Marcis Bajars, Juliane Manitz, Mary Ruisi, James L Gulley
Publikováno v:
Future Oncology. 18:1333-1342
Background: This study examined patients with advanced non-small-cell lung cancer who received long-term avelumab (anti-PD-L1) in a large phase Ib trial (JAVELIN Solid Tumor). Methods: Patients receiving >2 years of avelumab were reviewed and explora
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f2c5d0095ae85f3c365f5222dcb54d9a
https://doi.org/10.2217/fon-2021-0930
https://doi.org/10.2217/fon-2021-0930
Publikováno v:
BMJ Case Rep
A 57-year-old Southeast Asian woman with a remote history of adenoid cystic carcinoma (ACC) of the right labium superius oris (upper lip) presented to the hospital with vague epigastric pain. On workup, she was found to have multiple pleural nodules.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0848550ff1e4de419e18cbcf03b4524
https://pubmed.ncbi.nlm.nih.gov/33414116
https://pubmed.ncbi.nlm.nih.gov/33414116
Autor:
Keerthi, Gullapalli, Rohan M, Prasad, Abdullah, Al-Abcha, Zahin, Hussain, Aseel, Alsouqi, Osama, Mosalem, Borys, Hrinczenko
Publikováno v:
Cureus.
Due to a high risk of recurrent thromboembolism in patients with antiphospholipid syndrome (APS), long-term anticoagulation is recommended. For decades, vitamin K antagonists (VKAs) have been the gold standard for thromboprophylaxis in these patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3a34e7949a2bf1e4145524975404ad8
https://doi.org/10.7759/cureus.29449
https://doi.org/10.7759/cureus.29449
Publikováno v:
American Journal of Gastroenterology. 117:e1972-e1973
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b596b654623b7aea032e18fed99b3d80
https://doi.org/10.14309/01.ajg.0000868864.27134.f8
https://doi.org/10.14309/01.ajg.0000868864.27134.f8
Publikováno v:
Cureus
BRAF mutations are estimated to be present in 2-4% of non-small cell lung carcinoma (NSCLC) cases. BRAF inhibitor (dabrafenib) and MEK inhibitor (trametinib) are currently approved to treat NSCLC harboring the BRAF V600E mutation. However, the use of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8cf9d8c602fa06a50bc8c6bdef2a58f9
http://europepmc.org/articles/PMC8396418
http://europepmc.org/articles/PMC8396418
Autor:
Greg Andrew Durm, Hirva Mamdani, Sandra K. Althouse, Salma K. Jabbour, Apar Kishor Ganti, Shadia Ibrahim Jalal, Jason Alan Chesney, Jarushka Naidoo, Borys Hrinczenko, Mary Jo J. Fidler, Ticiana Leal, Lawrence Eric Feldman, Naomi Fujioka, Nasser H. Hanna
Publikováno v:
Journal of Clinical Oncology. 40:8509-8509
8509 Background: The PACIFIC trial demonstrated that a year of consolidation PD-(L)1 inhibition following concurrent chemoradiation (CRT) for unresectable stage III NSCLC improves overall survival (OS). The optimal duration of consolidation IO therap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::376bab74bf1882e6895e98786b9d7c04
https://doi.org/10.1200/jco.2022.40.16_suppl.8509
https://doi.org/10.1200/jco.2022.40.16_suppl.8509
Autor:
Maxwell Oluwole Akanbi, Orimisan Samuel Adekolujo, Dan Isaac, Ahsan Wahab, Ling Wang, Borys Hrinczenko
Publikováno v:
Journal of Clinical Oncology. 40:10506-10506
10506 Background: In 2013, the USPSTF recommended screening for lung cancer with low-dose chest computed tomography (LDCT). This was based on the results of the National Lung Screening Trial which showed a 20% relative reduction in mortality from LDC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ff229c88042c5c47a1583810d854036b
https://doi.org/10.1200/jco.2022.40.16_suppl.10506
https://doi.org/10.1200/jco.2022.40.16_suppl.10506